Illumina has named Fredrick Clerie to be VP of quality assurance and regulatory affairs. Clerie previously was VP of global quality assurance and regulatory affairs for Bayer Healthcare and he spent nearly a decade in multiple positions at Bayer Diagnostics.
Signature Genomic Laboratories has named Evan Jones, the principal of jVen Capital, which recently invested in the company, to serve on its board of directors.
Jones was co-founder and chairman of the board of directors of Digene, which was acquired last year by Qiagen. He is now chairman of the board of directors for the Children’s Research Institute at the Children’s National Medical Center. He also is chairman of the Campaign for Public Health, and a member of the board of directors and executive committee at Research!America.
The J. Craig Venter Institute has named four staff promotions and advancements, including the promotion of Robert Friedman to deputy director of JCVI La Jolla, and three other promotions at the JCVI headquarters in Maryland.
Friedman formerly was VP of public policy, a role in which he focused on synthetic genomics and environmental genomics policies.
Karen Nelson has been appointed director of human microbiology and metagenomics in JCVI’s Human Genomic Medicine Group. Nelson currently is a principal investigator on a multi-center grant from the National Institutes of Health’s Human Microbiome Project.
Samuel Levy has been promoted to be director of human genomics at JCVI. Levy previously worked at Celera Genomics and he has been involved in Drosophila and human genome research.
Yu-Hui Rogers has been appointed VP of core technology development and services at JCVI. Rogers has worked in JCVI sequencing projects and she previously was manager of sequencing research and development at Celera.